Former Associate Editor
Robert T. Naismith, M.D., is Professor of Neurology and serves as Clinic Director and Director of Clinical Trials at the John L. Trotter MS Center at Washington University in St. Louis, MO. Interests include inflammatory diseases of the central nervous system, such as multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease. Specific research interests include clinical trials, outcome measures, MRI, and visual function.
Information about this editor was up to date at the time of their last affiliation with NEJM Clinician.
Alexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
National Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Consortium of Multiple Sclerosis Centers (Treasurer)